Your browser doesn't support javascript.
loading
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que, Yi; Zhang, Xiao-Long; Liu, Ze-Xian; Zhao, Jing-Jing; Pan, Qiu-Zhong; Wen, Xi-Zhi; Xiao, Wei; Xu, Bu-Shu; Hong, Dong-Chun; Guo, Tian-Hui; Shen, Lu-Jun; Fan, Wei-Jun; Chen, Huo-Ying; Weng, De-Sheng; Xu, Hai-Rong; Zhou, Peng-Hui; Zhang, Yi-Zhuo; Niu, Xiao-Hui; Zhang, Xing.
Afiliação
  • Que Y; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Zhang XL; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Liu ZX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Zhao JJ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Pan QZ; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Wen XZ; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Xiao W; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Xu BS; Department of Hematological Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Hong DC; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Guo TH; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Shen LJ; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Fan WJ; Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Chen HY; Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Weng DS; Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
  • Xu HR; Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Zhou PH; Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing, China.
  • Zhang YZ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Niu XH; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China zhangxing@sysucc.org.cn niuxiaohui@263.net zhangyzh@sysucc.org.cn.
  • Zhang X; Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing, China zhangxing@sysucc.org.cn niuxiaohui@263.net zhangyzh@sysucc.org.cn.
J Immunother Cancer ; 9(2)2021 02.
Article em En | MEDLINE | ID: mdl-33637599
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Histona Desacetilase 1 / Histona Desacetilase 2 / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico / Aminopiridinas / Histona Desacetilases / Lipossarcoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Histona Desacetilase 1 / Histona Desacetilase 2 / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico / Aminopiridinas / Histona Desacetilases / Lipossarcoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido